RBC Europe’s Grace Therapeutics GRCE Stock Holding History

RBC Europe’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	-$6	–	1187
2021 Q3	$6	Hold	1	–	–	﹤0.01%	1235
2021 Q2	$17	Hold	1	–	–	﹤0.01%	1224
2021 Q1	$18	Hold	1	–	–	﹤0.01%	1174
2020 Q4	$10	Hold	1	–	–	﹤0.01%	1148
2020 Q3	$6	Hold	1	–	–	﹤0.01%	1098
2020 Q2	$14	Hold	1	–	–	﹤0.01%	1061
2020 Q1	$11	Hold	1	–	–	﹤0.01%	1038
2019 Q4	$74	Hold	1	–	–	﹤0.01%	1034
2019 Q3	$57	Hold	1	–	–	﹤0.01%	1038
2019 Q2	$34	Hold	1	–	–	﹤0.01%	1058
2019 Q1	$31	Hold	1	–	–	﹤0.01%	1073
2018 Q4	$25	Hold	1	–	–	﹤0.01%	1085
2018 Q3	$39	Hold	1	–	–	﹤0.01%	1124
2018 Q2	$17	Hold	1	–	–	﹤0.01%	1140
2018 Q1	$31	Hold	1	–	–	﹤0.01%	1118
2017 Q4	$28	Hold	1	–	–	﹤0.01%	1131
2017 Q3	$43	Buy	+1	New	+$63	﹤0.01%	1128

Other funds holding GRCE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

RBC Europe's GRCE Position: Q4 2021 in Review

RBC Europe sold out of Grace Therapeutics (GRCE) in Q4 2021, closing a stake of 1 share — an estimated $6 sold.

RBC Europe first reported a position in GRCE in Q3 2017 and held it in 17 quarters. The position peaked at $74 in Q4 2019. 15 funds tracked by Wall St. Rank hold GRCE as of Q4 2021.

RBC Europe reported no remaining Grace Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 1 Grace Therapeutics share in Q4 2021, an estimated $6.
RBC Europe first reported a position in Grace Therapeutics in Q3 2017 and held it in 17 quarters.
RBC Europe's Grace Therapeutics position peaked at $74 in Q4 2019.
15 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.